The combination therapeutic strategies targeting PD-1/PD-L1 on TAMs synergistically improve the number and function of immune cells in the TME, thereby evoking anti-tumor immunity against solid tumors and facilitating the transition from “cold tumor” to “hot tumor.” The gene discussed is PDCD1; the disease is neoplasm.